Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
Tricou V, Eyre S, Ramjee M, Collini P, Mojares Z, Loeliger E, Mandaric S, Rauscher M, Brose M, Lefevre I, Folschweiller N, Wallace D. Tricou V, et al. Among authors: brose m. Vaccine. 2023 Feb 10;41(7):1398-1407. doi: 10.1016/j.vaccine.2023.01.007. Epub 2023 Jan 19. Vaccine. 2023. PMID: 36681529 Free article. Clinical Trial.
Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
Tricou V, Essink B, Ervin JE, Turner M, Escudero I, Rauscher M, Brose M, Lefevre I, Borkowski A, Wallace D. Tricou V, et al. Among authors: brose m. PLoS Negl Trop Dis. 2023 Mar 8;17(3):e0011124. doi: 10.1371/journal.pntd.0011124. eCollection 2023 Mar. PLoS Negl Trop Dis. 2023. PMID: 36888687 Free PMC article. Clinical Trial.
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
Sirivichayakul C, Biswal S, Saez-Llorens X, López-Medina E, Borja-Tabora C, Bravo L, Kosalaraksa P, Alera MT, Reynales H, Rivera L, Watanaveeradej V, Yu D, Espinoza F, Dietze R, Fernando L, Wickramasinghe VP, Moreira ED Jr, Fernando AD, Gunasekera D, Luz K, Venâncio da Cunha R, Oliveira AL, Rauscher M, Fan H, Borkowski A, Escudero I, Tuboi S, Lloyd E, Tricou V, Folschweiller N, LeFevre I, Vargas LM, Wallace D; TIDES Study Group. Sirivichayakul C, et al. J Infect Dis. 2024 Apr 29:jiae222. doi: 10.1093/infdis/jiae222. Online ahead of print. J Infect Dis. 2024. PMID: 38682569
Proposal and practicality of an alternative blue-light hazard risk assessment method for high-intensity white-light sources at workplaces.
Bauer S, Berget M, Borra M, Brissinger D, Brose M, Görlich S, Halbritter W, Heepenstrick T, Janßen M, Kitz E, Kubica JM, Łowcewicz M, Marro M, Militello A, Pelko M, Rybczyński A, Weber M, Wolska A. Bauer S, et al. Among authors: brose m. Int J Occup Saf Ergon. 2024 Jun;30(2):450-459. doi: 10.1080/10803548.2024.2317050. Epub 2024 Apr 4. Int J Occup Saf Ergon. 2024. PMID: 38378446
Natural reversion promotes LPS elongation in an attenuated Coxiella burnetii strain.
Long CM, Beare PA, Cockrell D, Binette P, Tesfamariam M, Richards C, Anderson M, McCormick-Ell J, Brose M, Anderson R, Omsland A, Pearson T, Heinzen RA. Long CM, et al. Among authors: brose m. Nat Commun. 2024 Jan 24;15(1):697. doi: 10.1038/s41467-023-43972-y. Nat Commun. 2024. PMID: 38267444 Free PMC article.
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Makker V, Taylor MH, Aghajanian C, Cohn AL, Brose MS, Simone CD, Cao ZA, Suttner L, Loboda A, Cristescu R, Jelinic P, Orlowski R, Dutta L, Matsui J, Dutcus CE, Minoshima Y, Messing MJ. Makker V, et al. Among authors: brose ms. J Immunother Cancer. 2024 Jan 19;12(1):e007929. doi: 10.1136/jitc-2023-007929. J Immunother Cancer. 2024. PMID: 38242717 Free PMC article.
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Williamson D, Levytskyy R, Oliver J, Keam B, Brose MS. Capdevila J, et al. Among authors: brose ms. Thyroid. 2024 Mar;34(3):347-359. doi: 10.1089/thy.2023.0463. Epub 2024 Jan 23. Thyroid. 2024. PMID: 38062732 Free PMC article. Clinical Trial.
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Subbiah V, et al. Among authors: brose ms. Thyroid. 2024 Jan;34(1):26-40. doi: 10.1089/thy.2023.0363. Thyroid. 2024. PMID: 38009200
145 results